M&A / Deals Insilico Medicine, Takeda partner on AI-driven drug discovery Pharmaceutical Business ReviewUnder the agreement, Insilico will lead efforts using AI to identify molecules that meet predefined scientific and early development criteria.Read full story pharminent July 2, 2026 (Last updated: July 3, 2026) Pharmaceutical Business Review Under the agreement, Insilico will lead efforts using AI to identify molecules that meet predefined scientific and early development criteria. Read full story Post navigation Previous: FDA Selects Seven for PreCheck Pilot to Advance Drug ManufacturingNext: Roche’s KRAS drug tops its rivals in lung cancer trial Related Stories M&A / Deals Exegenesis Bio and Modalis sign research deal for Duchenne therapy pharminent September 11, 2026 M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026